Abstract: The invention relates to a bacterial strain of species Faecalibacterium prausnitzii deposited at the CNCM under access number CNCM I-4573, for use in the treatment and/or prevention of an inflammatory gastrointestinal illness in an individual.

Abstract: The present invention relates to a FGF19 polypeptide for its use as an agent increasing muscle fibers size, in the prevention and/or treatment of muscle atrophy in a mammal body.

Abstract: The present disclosure relates to the use of a biopolymer as a sensitive material in a dielectric gas sensor for water vapor, carbon dioxide, and/or ethanol.

Abstract: This invention relates to the use of a yeast strain overexpressing at least the following genes: the ALK3 gene, at least one of genes ADH2 and ADH5 and at least one of genes FALDH3 and FALDH4, or gene FA01, for the fermentation-based production of carboxylic diacids.

Abstract: Alpha/alpha-prime/alkoxylated glycerol linear carbonic esters have formula (VI): where p is an integer higher than 1, x is an integer equaling 0 or 1 with x not always being zero, and M1 is hydrogen (H). Q1 can be a hydrocarbon aliphatic group, an amino hydrocarbon group or an oxygenated amino hydrocarbon group. G1 can be an ?/??-alkoxylated propyl group of general formula (II?): where R4, R5 and R6 are variously hydrogen (H), an alkyl or an amino-alkyl group having 1 to 5 carbon atoms, or general formula (VII): where R7 is a H or a hydrocarbon group having 1 to 6 carbon atoms, and m is an integer between 0 and 10 inclusive, and X is —O— or —NH—.

Abstract: Disclosed is a method for producing nanocelluloses from a cellulose substrate including cellulose fibers, the method including the following sequence of steps: a step of enzymatic treatment of the cellulose substrate, by bringing same into contact with at least one cleaving enzyme, then a step of mechanical treatment of the cellulose substrate subjected to the step of enzymatic treatment, in order to delaminate the cellulose fibres and obtain the nanocelluloses. The at least one cleaving enzyme is chosen from the enzymes belonging to the family of lytic polysaccharide monooxygenases (LPMOs) capable of achieving cleavage in the presence of an electron donor. Also disclosed are the nanocelluloses obtained according to the method.

Abstract: The present invention relates to the use of a cysteine endoprotease or a malt extract to prevent or reduce the cloudiness of a cereal-based beverage, fermented or not.

Abstract: A method for the synthesis of ?/??-alcoxylated glycerol linear carbonic esters, wherein the following are brought into contact at a reaction temperature lower than 220° C.: a quantity of at least one precursor selected from the group consisting of ?/??-alcoxylated glycerol cyclo-carbonates; a quantity of at least one catalyst selected from the group consisting of metal oxides, Lewis acids, organometallic catalysts and mineral bases; and a quantity of at least one organic primer. A composition containing at least one novel ?/??-alkoxylated glycerol linear carbonic ester.

Abstract: The use of a polyhydroxylated polyaromatic compound, in particular of chicoric acid, for combating plant pests and phytosanitary composition comprising chicoric acid.

Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.

Abstract: A new cultivar of Abelia plant named, ‘ABENOV41’ that is characterized by its an evergreen plant habit in U.S.D.A. Zone 7, its long and floriferous bloom period, blooming from May to October in France, its large flowers that are pink-violet in color and open from deep pink-purple buds, its bracts that are reddish brown in color, and its moderate to vigorous growth habit.

Abstract: The present invention concerns the use of a furfural derivative of formula (I) in which R represents (i) a —CH?CR?1—COR1 group, a group a group a group or a —CHO and R? represents a hydrogen atom or a (C1-C4)alkyl group, as a chemical vehicle, as a solvent, co-solvent, coalescing agent, crystallization inhibitor, plasticising agent, degreasing agent, etchant, cleaning agent or agent for increasing biological activity, and more particularly as a solvent. It also concerns phytosanitary formulations or resin-solubilising formulations comprising at least one such furfural derivative of formula (I).

Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.

Abstract: The composition, advantageously an emulsion or a foam, includes an internal phase dispersed in a hydrophilic continuous phase, the percentage of the internal phase being higher than 50%. The emulsion composition contains nanocrystals of a polysaccharide other than cellulose, advantageously chitin, that are located at the interface between the internal phase and the hydrophilic continuous phase.

Abstract: Methods and compositions (such as pharmaceutical compositions) for treating influenza virus type A infections in human subjects include PAR2 agonists being administered to the subject. The PAR2 agonists include small organic molecules, antibodies, and aptamers. In addition, the PAR2 agonist may be a PAR2 activating peptide. Exemplary PAR2 activating peptides include SLIGRL (SEQ ID NO: 1) and SLIGKV (SEQ ID NO: 2).

Abstract: The present invention relates to a mutated nucleic acid sequence of a delta-12 oleate desaturase enzyme (FAD2)—encoding nucleic acid from a Cruciferae plant, wherein said mutated nucleic acid sequence comprises the non-conservative mutation of at least one nucleotide of at least one codon representing an amino acid selected from the group consisting of: —the amino acid at position 259 of the amino acid sequence of said FAD2, —the amino acid at position 216 of the amino acid sequence of said FAD2, —the amino acid at position 90 of the amino acid sequence of said FAD2, —the amino acid at position 116 of the amino acid sequence of said FAD2, —the amino acid at position 276 of the amino acid sequence of said FAD2.

Abstract: A combination product includes as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme and citrulline, or a bioequivalent compound thereof, for treating excess weight or obesity and/or the accumulation of body fat. A cosmetic treatment method for improving or slimming the figure and/or for stimulating the loss of excess weight and/or of cellulite and/or for limiting the accumulation thereof, includes the administration of a combination product including as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme or a physiologically acceptable salt thereof, and citrulline, or a bioequivalent compound thereof, or one of theirs analogues, and the renewal of the administration until the expected cosmetic effect is obtained. The combination product such as previously defined for improving or slimming the figure and/or for stimulating the loss of excess weight and/or of cellulite and/or for limiting the accumulation thereof is also described.

Abstract: Treatment of plants against infection by oomycetes. The invention refers to a new strain of Phoma useful for manufacturing a plant-care composition intended to treat plants against phytopathogenic oomycetes. This new strain was deposited on Feb. 25, 2010 with the Collection Nationale de Cultures de Microorganismes of the Institut Pasteur in Paris, France under the CNCM number I-4278.

Abstract: The invention relates to the use of the compound hesperidin or of one of its derivatives for the manufacture of a composition designed to stimulate bone formation and/or inhibit bone resorption in man or animals.

Abstract: A new cultivar of Abelia plant named, ‘ABENOV41’ that is characterized by its an evergreen plant habit in U.S.D.A. Zone 7, its long and floriferous bloom period, blooming from May to October in France, its large flowers that are pink-violet in color and open from deep pink-purple buds, its bracts that are reddish brown in color, and its moderate to vigorous growth habit.